Trials / Completed
CompletedNCT01078155
Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 131 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This post marketing observational study will be conducted in a prospective, single country, multicenter format to assess the prevention of generalized bone loss in patients with active rheumatoid arthritis (RA) treated with adalimumab (Humira®) in pragmatic prescribing situations. The investigational sites will be centers with experience in the treatment of RA patients and anti-tumor necrosis factor-alpha (TNF-a) therapy. The investigators will be rheumatologists authorized by the Czech Rheumatologic Society for prescribing biological treatment.
Conditions
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2014-05-01
- Completion
- 2014-05-01
- First posted
- 2010-03-02
- Last updated
- 2015-06-26
- Results posted
- 2015-05-29
Source: ClinicalTrials.gov record NCT01078155. Inclusion in this directory is not an endorsement.